EBS: Emergent BioSolutions Inc. Stock

by  •  • Comments Off on EBS: Emergent BioSolutions Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 264.08
Enterprise Value ($M) 829.08
Book Value ($M) 482.80
Book Value / Share 8.89
Price / Book 0.55
NCAV ($M) -308.20
NCAV / Share -5.67
Price / NCAV -0.86

Profitability (mra)
Return on Invested Capital (ROIC) -0.16
Return on Assets (ROA) -0.11
Return on Equity (ROE) -0.29

Liquidity (mrq)
Quick Ratio 1.77
Current Ratio 3.69

Balance Sheet (mrq) ($M)
Current Assets 598.70
Assets 1,389.70
Liabilities 906.90
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 1,043.60
Operating Income 42.90
Net Income -190.60
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 58.70
Cash from Investing 125.20
Cash from Financing -190.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-13 13G Oak Hill Advisors Lp 6.39
11-08 13G/A Charles Schwab Investment Management Inc 4.20 -22.59
09-10 13G/A BlackRock, Inc. 3.70 -48.72

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-04 10-K Form 10-K for the fiscal year ended December 31, 2024
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-01 160,876 1,124,048 14.31
2025-03-31 527,458 2,319,124 22.74
2025-03-28 171,963 1,152,411 14.92
2025-03-27 310,688 1,440,902 21.56

(click for more detail)

Similar Companies
BHC – Bausch Health Companies Inc. BHVN – Biohaven Ltd.
BMY – Bristol-Myers Squibb Company ELAN – Elanco Animal Health Incorporated
ENZ – Enzo Biochem, Inc.


Financial data and stock pages provided by
Fintel.io